Celgene Corp (CELG) 100.09 $CELG
Five Prime Therapeutics Carves Out Tighter Base
at Investor's Business Daily - Wed Mar 30, 5:39PM CDT
Around the turn of the millennium, the Human Genome Project, with all its potential therapies, was a big factor of huge moves in biotech stocks. But what about the extracellular proteome, or the immunome? Five Prime Therapeutics (FPRX) has a library...
BIIB: 260.32 (+6.14), GILD: 91.86 (-0.11), BMY: 63.88 (+0.44), CELG: 100.09 (+1.29), FPRX: 40.63 (+0.79)
Stock Market News for March 30, 2016
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 9:10AM CDT
Benchmarks finished in the green on Tuesday after Fed Chairwoman Janet Yellen indicated that the Fed will take a cautious stance before hiking interest rates.
BIIB: 260.32 (+6.14), V: 76.48 (-0.30), FB: 114.10 (-0.60), ALXN: 139.22 (+4.40), ILMN: 162.11 (+4.68), MYL: 46.35 (-0.05), GOOGL: 762.90 (-5.44), MSFT: 55.23 (+0.18), VZ: 54.08 (+0.04), AAPL: 108.99 (-0.57), CELG: 100.09 (+1.29)
How 16 Ex-Military CEOs are Trouncing Wall Street
at The Street - Mon Mar 28, 3:44PM CDT
Putting your money into these 16 companies, whose CEOs served in the U.S. military, would have left you (a lot) richer than just following the S&P 500.
FDX: 162.72 (+1.15), NSC: 83.25 (-1.50), CAM: 67.05 (-0.63), AAP: 160.34 (-3.45), PCG: 59.72 (+0.28), SNA: 156.99 (-1.55), RTN: 122.63 (-1.13), AMT: 102.37 (+0.06), SLB: 73.75 (-0.66), CELG: 100.09 (+1.29), SJM: 129.84 (-0.34), JNJ: 108.20 (-0.78), VNO: 94.43 (+0.46), CSC: 34.39 (+0.36), EQIX: 330.71 (+2.60), CSRA: 26.90 (-0.29), VZ: 54.08 (+0.04)
Krispy Is Kremed; RIP Andy Grove; Biotechs in No-Man's Land: Jim Cramer's Best Blogs
at The Street - Fri Mar 25, 8:00PM CDT
Cramer dissects Krispy Kreme, honors a tech pioneer and laments the state of biotech stocks.
BIIB: 260.32 (+6.14), VRX: 26.30 (-0.77), WMT: 68.49 (-0.31), INTC: 32.35 (-0.36), SHLD: 15.31 (+0.19), AGN: 268.03 (-6.91), SBUX: 59.70 (-0.31), JACK: 63.87 (-0.59), JNJ: 108.20 (-0.78), DNKN: 47.17 (+0.19), IBM: 151.45 (+3.04), CMG: 470.97 (+4.82), ABBV: 57.12 (+0.12), SNY: 40.16 (-0.53), KKD: 15.59 (+0.16), REGN: 360.44 (+0.76), HD: 133.43 (+0.01), PFE: 29.64 (-0.43), LLY: 72.01 (+0.23), GSK: 40.55 (-0.15), BMY: 63.88 (+0.44), PLKI: 52.06 (+0.28), DIN: 93.43 (-0.91), CELG: 100.09 (+1.29), QSR: 38.83 (-0.50), GILD: 91.86 (-0.11), MRK: 52.91 (-0.31), AZN: 28.16 (-0.16), MCD: 125.68 (-0.15), WEN: 10.89 (+0.03)
10 Women Who Would Be a Great Addition to Any Company's Board
at The Street - Thu Mar 24, 12:03PM CDT
Seven companies in the S&P 500 have no women on their boards. Maybe they're having trouble finding the right women? We aren't. Here are 10 that would make great additions.
CXO: 101.04 (-0.91), HST: 16.70 (+0.24), MDLZ: 40.12 (-0.34), HON: 112.05 (-0.12), CAH: 81.95 (+0.17), KORS: 56.96 (+0.09), IDA: 74.59 (-0.06), DO: 21.73 (+0.35), AMAT: 21.18 (+0.14), EOG: 72.58 (-1.08), MSFT: 55.23 (+0.18), REV: 36.41 (+0.53), MU: 10.47 (-0.01), HAR: 89.04 (+2.03), SWKS: 77.90 (+0.05), PFE: 29.64 (-0.43), MCHP: 48.20 (-0.64), LLTC: 44.56 (-0.22), UL: 45.18 (-0.59), MGM: 21.44 (+0.15), CELG: 100.09 (+1.29), GILD: 91.86 (-0.11), TXN: 57.42 (-0.95), MRK: 52.91 (-0.31), QLGC: 13.44 (+0.06), ADI: 59.19 (+0.08), MRO: 11.14 (+0.61), CVX: 95.40 (+0.15), XRAY: 61.63 (-0.43), NVS: 72.44 (-0.11), GRMN: 39.96 (+0.10), CCE: 50.74 (-0.35), K: 76.55 (-0.28), JNPR: 25.51 (unch), IBM: 151.45 (+3.04), APA: 48.81 (+0.17), GOOGL: 762.90 (-5.44), TER: 21.59 (+0.03), ALGN: 72.69 (+0.68), MET: 43.94 (-0.79), DISCA: 28.63 (+0.54), FCAU: 8.06 (-0.09), ISIL: 13.37 (+0.02), ORCL: 40.91 (-0.06), SQ: 15.28 (+0.26), GS: 156.98 (+0.48), QRVO: 50.41 (-0.82), LRCX: 82.60 (+0.41), BAX: 41.08 (-0.18), GM: 31.43 (+0.44), CRUS: 36.41 (+0.08), PG: 82.31 (-0.37), AVGO: 154.50 (-2.43), GSBD: 19.60 (+0.07), CRM: 73.83 (-0.47)
Attention Celgene Investors: New Competition Is on the Horizon
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 24, 8:02AM CDT
Image source: Pixabay. Shareholders of drug giant Celgene have very little to complain about, even if shares are off 13% on a trailing 12-month basis. If we back out our perspective a bit, Celgene shares are up more than 250% over the trialing...
JNJ: 108.20 (-0.78), CELG: 100.09 (+1.29)
Better Buy: Inovio Pharmaceuticals Inc. vs. Juno Therapeutics
Keith Speights, The Motley Fool - Motley Fool - Wed Mar 23, 2:37PM CDT
Image Source: Inovio Pharmaceuticals At first glance, Inovio Pharmaceuticals and Juno Therapeutics might appear to have little in common. Inovio focuses on synthetic DNA immunotherapies, while Juno has hitched its wagon to chimeric antigen...
INO: 8.71 (+0.08), JUNO: 38.09 (+1.16), CELG: 100.09 (+1.29)
TIAA-CREF’s Top Three Large Cap Growth Stocks
at The Street - Wed Mar 23, 1:50PM CDT
Value has outperformed growth thus far in 2016, but don't expect that lead to last, especially for stocks like Celgene, Norwegian Cruise Line and Intuit.
NCLH: 55.29 (+1.11), INTU: 104.01 (+0.83), CELG: 100.09 (+1.29)
Onconova Starts Phase III INSPIRE Study on Rigosertib in EU
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 8:30AM CDT
Onconova (ONTX) initiates patient enrolment in the phase III INSPIRE study on IV rigosertib in the EU.
SHPG: 171.90 (+3.40), ONTX: 0.58 (-0.01), BXLT: 40.40 (+0.25), CELG: 100.09 (+1.29)
Stocks Run in Place as Brussels Attack Paralyzes Wall Street
at The Street - Tue Mar 22, 3:09PM CDT
A quieter holiday trading week was disrupted by tragedy on Tuesday, with dual explosions at a Brussels airport and metro station reigniting global concerns about terrorism.
VRX: 26.30 (-0.77), DAL: 48.68 (-0.65), PFE: 29.64 (-0.43), DB: 16.94 (-0.18), LL: 13.12 (+0.21), PCLN: 1,288.96 (-28.07), CELG: 100.09 (+1.29), UAL: 59.86 (+0.04), LUV: 44.80 (-0.18), GILD: 91.86 (-0.11), EXPE: 107.82 (+0.02), AAL: 41.01 (-0.37), AAPL: 108.99 (-0.57), IHG: 41.27 (+0.98)
Are These Biotech Stocks Worth your Attention? CELG, ARIA, EXEL, and CMRX
ACCESSWIRE - Tue Mar 22, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 22, 2016 / Despite the challenges that continue to press the Biotech industry, ValuableInvestment.com, this morning, turns its focus on the following Healthcare companies: Celgene Corp. (NASDAQ: CELG), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Exelixis Inc. (NASDAQ: EXEL), and Chimerix Inc. (NASDAQ: CMRX). Find out why these stocks are under our microscope by clicking the link below:
CMRX: 5.11 (+0.14), ARIA: 6.39 (+0.19), EXEL: 4.00 (+0.10), CELG: 100.09 (+1.29), CELGZ: 1.31 (+0.11)
Cramer: The Biotech Stocks Are in No Man's Land Right Now
at The Street - Tue Mar 22, 5:17AM CDT
The group rallied yesterday, but it's still not out of the woods.
AGN: 268.03 (-6.91), BIIB: 260.32 (+6.14), VRX: 26.30 (-0.77), BMY: 63.88 (+0.44), CELG: 100.09 (+1.29)
Celgene & Pfizer Present Data from Ulcerative Colitis Trials
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 12:20PM CDT
Celgene (CELG) and Pfizer (PFE) have presented data from their ulcerative colitis study at the 11th Congress of the European Crohn's and Colitis Organisation.
PFE: 29.64 (-0.43), HZNP: 16.57 (+0.56), ANIK: 44.72 (-0.26), CELG: 100.09 (+1.29)
Look for Shares of Celgene to Potentially Pullback after Yesterday's 2.07% Rise
Comtex SmarTrend(R) - Mon Mar 21, 12:17PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $98.22 to a high of $100.80. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $99.26 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 100.09 (+1.29)
Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial
BusinessWire - Fri Mar 18, 12:47PM CDT
--A greater proportion of patients achieved histologic remission at week 32 with ozanimod 1 mg versus placebo
CELG: 100.09 (+1.29)
Will Celgene Whiff on Its 2017 Guidance?
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 18, 8:41AM CDT
IMAGE SOURCE: CELGENE CORPORATION. Worry that the company may not be able to deliver on its long-standing sales target for 2017 may be to blame for Celgene Corporation 's shares failing to budge this year. According to Celgene's management,...
CELG: 100.09 (+1.29)
Don't Rely on the Luck of the Irish When Picking Sectors and Stocks
at The Street - Thu Mar 17, 9:00AM CDT
It's better to broaden your exposure to avoid seeing your portfolio suffer.
AGN: 268.03 (-6.91), GILD: 91.86 (-0.11), AMGN: 149.93 (+0.45), TEVA: 53.51 (-0.89), CELG: 100.09 (+1.29)
Is This Celgene's Biggest Milestone in 2016
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 16, 3:21PM CDT
SOURCE: CELGENE CORPORATION. At a recent investor conference, Celgene Corporation 's President Jacqualyn Fouse highlighted upcoming trial results that could be the company's biggest news this year. Celgene is studying the use of its multibillion...
CELG: 100.09 (+1.29)
Five Prime Therapeutics Carves Out Tighter Base
at Investor's Business Daily - Wed Mar 30, 5:39PM CDT
Around the turn of the millennium, the Human Genome Project, with all its potential therapies, was a big factor of huge moves in biotech stocks. But what about the extracellular proteome, or the immunome? Five Prime Therapeutics (FPRX) has a library...
BIIB: 260.32 (+6.14), GILD: 91.86 (-0.11), BMY: 63.88 (+0.44), CELG: 100.09 (+1.29), FPRX: 40.63 (+0.79)
Stock Market News for March 30, 2016
Zacks Equity Research - Zacks Investment Research - Wed Mar 30, 9:10AM CDT
Benchmarks finished in the green on Tuesday after Fed Chairwoman Janet Yellen indicated that the Fed will take a cautious stance before hiking interest rates.
BIIB: 260.32 (+6.14), V: 76.48 (-0.30), FB: 114.10 (-0.60), ALXN: 139.22 (+4.40), ILMN: 162.11 (+4.68), MYL: 46.35 (-0.05), GOOGL: 762.90 (-5.44), MSFT: 55.23 (+0.18), VZ: 54.08 (+0.04), AAPL: 108.99 (-0.57), CELG: 100.09 (+1.29)
How 16 Ex-Military CEOs are Trouncing Wall Street
at The Street - Mon Mar 28, 3:44PM CDT
Putting your money into these 16 companies, whose CEOs served in the U.S. military, would have left you (a lot) richer than just following the S&P 500.
FDX: 162.72 (+1.15), NSC: 83.25 (-1.50), CAM: 67.05 (-0.63), AAP: 160.34 (-3.45), PCG: 59.72 (+0.28), SNA: 156.99 (-1.55), RTN: 122.63 (-1.13), AMT: 102.37 (+0.06), SLB: 73.75 (-0.66), CELG: 100.09 (+1.29), SJM: 129.84 (-0.34), JNJ: 108.20 (-0.78), VNO: 94.43 (+0.46), CSC: 34.39 (+0.36), EQIX: 330.71 (+2.60), CSRA: 26.90 (-0.29), VZ: 54.08 (+0.04)
Krispy Is Kremed; RIP Andy Grove; Biotechs in No-Man's Land: Jim Cramer's Best Blogs
at The Street - Fri Mar 25, 8:00PM CDT
Cramer dissects Krispy Kreme, honors a tech pioneer and laments the state of biotech stocks.
BIIB: 260.32 (+6.14), VRX: 26.30 (-0.77), WMT: 68.49 (-0.31), INTC: 32.35 (-0.36), SHLD: 15.31 (+0.19), AGN: 268.03 (-6.91), SBUX: 59.70 (-0.31), JACK: 63.87 (-0.59), JNJ: 108.20 (-0.78), DNKN: 47.17 (+0.19), IBM: 151.45 (+3.04), CMG: 470.97 (+4.82), ABBV: 57.12 (+0.12), SNY: 40.16 (-0.53), KKD: 15.59 (+0.16), REGN: 360.44 (+0.76), HD: 133.43 (+0.01), PFE: 29.64 (-0.43), LLY: 72.01 (+0.23), GSK: 40.55 (-0.15), BMY: 63.88 (+0.44), PLKI: 52.06 (+0.28), DIN: 93.43 (-0.91), CELG: 100.09 (+1.29), QSR: 38.83 (-0.50), GILD: 91.86 (-0.11), MRK: 52.91 (-0.31), AZN: 28.16 (-0.16), MCD: 125.68 (-0.15), WEN: 10.89 (+0.03)
10 Women Who Would Be a Great Addition to Any Company's Board
at The Street - Thu Mar 24, 12:03PM CDT
Seven companies in the S&P 500 have no women on their boards. Maybe they're having trouble finding the right women? We aren't. Here are 10 that would make great additions.
CXO: 101.04 (-0.91), HST: 16.70 (+0.24), MDLZ: 40.12 (-0.34), HON: 112.05 (-0.12), CAH: 81.95 (+0.17), KORS: 56.96 (+0.09), IDA: 74.59 (-0.06), DO: 21.73 (+0.35), AMAT: 21.18 (+0.14), EOG: 72.58 (-1.08), MSFT: 55.23 (+0.18), REV: 36.41 (+0.53), MU: 10.47 (-0.01), HAR: 89.04 (+2.03), SWKS: 77.90 (+0.05), PFE: 29.64 (-0.43), MCHP: 48.20 (-0.64), LLTC: 44.56 (-0.22), UL: 45.18 (-0.59), MGM: 21.44 (+0.15), CELG: 100.09 (+1.29), GILD: 91.86 (-0.11), TXN: 57.42 (-0.95), MRK: 52.91 (-0.31), QLGC: 13.44 (+0.06), ADI: 59.19 (+0.08), MRO: 11.14 (+0.61), CVX: 95.40 (+0.15), XRAY: 61.63 (-0.43), NVS: 72.44 (-0.11), GRMN: 39.96 (+0.10), CCE: 50.74 (-0.35), K: 76.55 (-0.28), JNPR: 25.51 (unch), IBM: 151.45 (+3.04), APA: 48.81 (+0.17), GOOGL: 762.90 (-5.44), TER: 21.59 (+0.03), ALGN: 72.69 (+0.68), MET: 43.94 (-0.79), DISCA: 28.63 (+0.54), FCAU: 8.06 (-0.09), ISIL: 13.37 (+0.02), ORCL: 40.91 (-0.06), SQ: 15.28 (+0.26), GS: 156.98 (+0.48), QRVO: 50.41 (-0.82), LRCX: 82.60 (+0.41), BAX: 41.08 (-0.18), GM: 31.43 (+0.44), CRUS: 36.41 (+0.08), PG: 82.31 (-0.37), AVGO: 154.50 (-2.43), GSBD: 19.60 (+0.07), CRM: 73.83 (-0.47)
Attention Celgene Investors: New Competition Is on the Horizon
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 24, 8:02AM CDT
Image source: Pixabay. Shareholders of drug giant Celgene have very little to complain about, even if shares are off 13% on a trailing 12-month basis. If we back out our perspective a bit, Celgene shares are up more than 250% over the trialing...
JNJ: 108.20 (-0.78), CELG: 100.09 (+1.29)
Better Buy: Inovio Pharmaceuticals Inc. vs. Juno Therapeutics
Keith Speights, The Motley Fool - Motley Fool - Wed Mar 23, 2:37PM CDT
Image Source: Inovio Pharmaceuticals At first glance, Inovio Pharmaceuticals and Juno Therapeutics might appear to have little in common. Inovio focuses on synthetic DNA immunotherapies, while Juno has hitched its wagon to chimeric antigen...
INO: 8.71 (+0.08), JUNO: 38.09 (+1.16), CELG: 100.09 (+1.29)
TIAA-CREF’s Top Three Large Cap Growth Stocks
at The Street - Wed Mar 23, 1:50PM CDT
Value has outperformed growth thus far in 2016, but don't expect that lead to last, especially for stocks like Celgene, Norwegian Cruise Line and Intuit.
NCLH: 55.29 (+1.11), INTU: 104.01 (+0.83), CELG: 100.09 (+1.29)
Onconova Starts Phase III INSPIRE Study on Rigosertib in EU
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 8:30AM CDT
Onconova (ONTX) initiates patient enrolment in the phase III INSPIRE study on IV rigosertib in the EU.
SHPG: 171.90 (+3.40), ONTX: 0.58 (-0.01), BXLT: 40.40 (+0.25), CELG: 100.09 (+1.29)
Stocks Run in Place as Brussels Attack Paralyzes Wall Street
at The Street - Tue Mar 22, 3:09PM CDT
A quieter holiday trading week was disrupted by tragedy on Tuesday, with dual explosions at a Brussels airport and metro station reigniting global concerns about terrorism.
VRX: 26.30 (-0.77), DAL: 48.68 (-0.65), PFE: 29.64 (-0.43), DB: 16.94 (-0.18), LL: 13.12 (+0.21), PCLN: 1,288.96 (-28.07), CELG: 100.09 (+1.29), UAL: 59.86 (+0.04), LUV: 44.80 (-0.18), GILD: 91.86 (-0.11), EXPE: 107.82 (+0.02), AAL: 41.01 (-0.37), AAPL: 108.99 (-0.57), IHG: 41.27 (+0.98)
Are These Biotech Stocks Worth your Attention? CELG, ARIA, EXEL, and CMRX
ACCESSWIRE - Tue Mar 22, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / March 22, 2016 / Despite the challenges that continue to press the Biotech industry, ValuableInvestment.com, this morning, turns its focus on the following Healthcare companies: Celgene Corp. (NASDAQ: CELG), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Exelixis Inc. (NASDAQ: EXEL), and Chimerix Inc. (NASDAQ: CMRX). Find out why these stocks are under our microscope by clicking the link below:
CMRX: 5.11 (+0.14), ARIA: 6.39 (+0.19), EXEL: 4.00 (+0.10), CELG: 100.09 (+1.29), CELGZ: 1.31 (+0.11)
Cramer: The Biotech Stocks Are in No Man's Land Right Now
at The Street - Tue Mar 22, 5:17AM CDT
The group rallied yesterday, but it's still not out of the woods.
AGN: 268.03 (-6.91), BIIB: 260.32 (+6.14), VRX: 26.30 (-0.77), BMY: 63.88 (+0.44), CELG: 100.09 (+1.29)
Celgene & Pfizer Present Data from Ulcerative Colitis Trials
Zacks Equity Research - Zacks Investment Research - Mon Mar 21, 12:20PM CDT
Celgene (CELG) and Pfizer (PFE) have presented data from their ulcerative colitis study at the 11th Congress of the European Crohn's and Colitis Organisation.
PFE: 29.64 (-0.43), HZNP: 16.57 (+0.56), ANIK: 44.72 (-0.26), CELG: 100.09 (+1.29)
Look for Shares of Celgene to Potentially Pullback after Yesterday's 2.07% Rise
Comtex SmarTrend(R) - Mon Mar 21, 12:17PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $98.22 to a high of $100.80. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $99.26 on volume of 2.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 100.09 (+1.29)
Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial
BusinessWire - Fri Mar 18, 12:47PM CDT
--A greater proportion of patients achieved histologic remission at week 32 with ozanimod 1 mg versus placebo
CELG: 100.09 (+1.29)
Will Celgene Whiff on Its 2017 Guidance?
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 18, 8:41AM CDT
IMAGE SOURCE: CELGENE CORPORATION. Worry that the company may not be able to deliver on its long-standing sales target for 2017 may be to blame for Celgene Corporation 's shares failing to budge this year. According to Celgene's management,...
CELG: 100.09 (+1.29)
Don't Rely on the Luck of the Irish When Picking Sectors and Stocks
at The Street - Thu Mar 17, 9:00AM CDT
It's better to broaden your exposure to avoid seeing your portfolio suffer.
AGN: 268.03 (-6.91), GILD: 91.86 (-0.11), AMGN: 149.93 (+0.45), TEVA: 53.51 (-0.89), CELG: 100.09 (+1.29)
Is This Celgene's Biggest Milestone in 2016
Todd Campbell, The Motley Fool - Motley Fool - Wed Mar 16, 3:21PM CDT
SOURCE: CELGENE CORPORATION. At a recent investor conference, Celgene Corporation 's President Jacqualyn Fouse highlighted upcoming trial results that could be the company's biggest news this year. Celgene is studying the use of its multibillion...
CELG: 100.09 (+1.29)
